阿科生物®超群(袋装)

Arkobiotics®Supraflor益生菌(袋装)

Arkobiotics® Supraflor 是基于乳酸酵素的膳食补充剂。 它融合了Rosell-Lallemand 研究所严格挑选的6种乳酸发酵菌株 :

  • 长双歧杆菌Rosell-175,
  • 鼠李糖乳杆菌Rosell-11,
  • 瑞士乳杆菌Rosell-52,
  • 乳酸乳球菌Rosell-1058,
  • 动物双歧杆菌LAFTI B94,
  • 嗜酸乳杆菌Roselll-418.
13位条形码:3401560748154-10袋装
13位条形码:3401560748963-30袋装

口服.

  • 3岁以上儿童 : 每天1袋,随餐溶于大杯水中服用,最好在早餐时服用。可以将乳酸菌与食物混合(甜点慕斯、果泥,奶制品甜点......).
  • 勿超过每日建议用量.
  • 膳食补充剂不能替代平衡、多样的饮食以及健康的生活方式.
  • 请置于儿童不能触及的地方.
  • 请存储在25摄氏度以下的环境中,远离光照、高温和潮湿.

Stephani, J., Radulovic, K., and Niess, J.H. Gut microbiota, probiotics and inflammatory bowel disease. Archivum immunologiae et therapiae experimentalis. Vol 59 : 161-177(2011).

Hebuterne, X. Gut changes attributed to ageing: effects on intestinal microfl ora. Curr Opin Clin Nutr MetabCare. Vol 6 :49–54 (2003).

Zhang Y., Lixiang L., Chuanguo Guo., Dan Mu., Bingcheng Feng., Zuo Xiuli., Yanquing Li. Effects of probiotic type, dose and treatment duration on irritable bowel syndrome diagnosed by Romm II criteria : a meta-analysis. BMC Gastroenterology (2016).

Sarowska, J., Choroszy-Król, I., Regulska-Ilow, B., Frej-M drzak, M. & Jama-Kmiecik, A. The therapeutic effect of probiotic bacteria on gastrointestinal diseases.

Adv. Clin. Exp. Med. Off. Organ Wroclaw Med. Univ. 22, 759–766 (2013).

Marteau, P., Guyonnet, D., Lafaye de Micheaux, P. & Gelu, S. A randomized, double-blind, controlled study and pooled analysis of two identical trials of fermented milk containing probiotic Bifi dobacterium lactis CNCM I-2494 in healthy women reporting minor digestive symptoms.

Neurogastroenterol. Motil. Off. J. Eur. Gastrointest. Motil. Soc. 25, 331–e252 (2013).

Gawro ska, A., Dziechciarz, P., Horvath, A. & Szajewska, H. A randomized double-blind placebo-controlled trial of Lactobacillus GG for abdominal pain disorders in children.

Aliment. Pharmacol. Ther. 25, 177–184 (2007).

Del Piano, M. et al. The use of probiotics in healthy volunteers with evacuation disorders and hard stools: a double-blind, randomized, placebo-controlled study.

J. Clin. Gastroenterol. 44 Suppl 1, S30–34 (2010).

Zhang, L., Su, P., Henriksson, A., O’Rourke, J. & Mitchell, H. Investigation of the immunomodulatory effects of Lactobacillus casei and Bifi dobacterium lactis on Helicobacter pylori infection.

Helicobacter 13 :183–190 (2008).

Dylag, K., Hubalewska-Mazgaj, M., Surmiak, M., Szmyd, J. & Brzozowski, T. Probiotics in the mechanism of protection against gut inflammation and therapy of gastrointestinal disorders.

Curr. Pharm. Des. 20, 1149–1155 (2014).

Arkobiotics® Supraflor,高科技产品

作为欧洲植物疗法和膳食补充剂领域的专家和领导企业,Arkopharma为您提供Arkobiotics® Supraflor益生菌,配方结合了6个安全和经GRAS公认安全认证的乳酸菌菌株,并有最新科学进展支持:

  • 健康事业工作者的使用反馈.
  • 科学知识/研究.
  • 在胃酸和胆盐中的生存能力.
  • 在法国巴斯德研究所和加拿大罗塞尔研究所注册的菌株.


Arkobiotics® Supraflor的质量承诺

出厂时每粒胶囊含有55亿个乳酸菌。随着时间的推移,乳酸菌会自然减少.

特殊制造技术和超防护包装可保证最佳的储存和检验条件,以确保产品的高质量,Arkobiotics® Supraflor保证在保质期末每袋至少含10亿个菌落形成单位(CFU).


营养含量表 

  1袋
乳酸菌 10亿个菌落形成单位

Arkobiotics® Supraflor,高科技产品

作为欧洲植物疗法和膳食补充剂领域的专家和领导企业,Arkopharma为您提供Arkobiotics® Supraflor益生菌,配方结合了6个安全和经GRAS公认安全认证的乳酸菌菌株,并有最新科学进展支持:

  • 健康事业工作者的使用反馈.
  • 科学知识/研究.
  • 在胃酸和胆盐中的生存能力.
  • 在法国巴斯德研究所和加拿大罗塞尔研究所注册的菌株.


Arkobiotics® Supraflor的质量承诺

出厂时每粒胶囊含有55亿个乳酸菌。随着时间的推移,乳酸菌会自然减少.

特殊制造技术和超防护包装可保证最佳的储存和检验条件,以确保产品的高质量,Arkobiotics® Supraflor保证在保质期末每袋至少含10亿个菌落形成单位(CFU).


营养含量表 

  1袋
乳酸菌 10亿个菌落形成单位

口服.

  • 3岁以上儿童 : 每天1袋,随餐溶于大杯水中服用,最好在早餐时服用。可以将乳酸菌与食物混合(甜点慕斯、果泥,奶制品甜点......).
  • 勿超过每日建议用量.
  • 膳食补充剂不能替代平衡、多样的饮食以及健康的生活方式.
  • 请置于儿童不能触及的地方.
  • 请存储在25摄氏度以下的环境中,远离光照、高温和潮湿.

Stephani, J., Radulovic, K., and Niess, J.H. Gut microbiota, probiotics and inflammatory bowel disease. Archivum immunologiae et therapiae experimentalis. Vol 59 : 161-177(2011).

Hebuterne, X. Gut changes attributed to ageing: effects on intestinal microfl ora. Curr Opin Clin Nutr MetabCare. Vol 6 :49–54 (2003).

Zhang Y., Lixiang L., Chuanguo Guo., Dan Mu., Bingcheng Feng., Zuo Xiuli., Yanquing Li. Effects of probiotic type, dose and treatment duration on irritable bowel syndrome diagnosed by Romm II criteria : a meta-analysis. BMC Gastroenterology (2016).

Sarowska, J., Choroszy-Król, I., Regulska-Ilow, B., Frej-M drzak, M. & Jama-Kmiecik, A. The therapeutic effect of probiotic bacteria on gastrointestinal diseases.

Adv. Clin. Exp. Med. Off. Organ Wroclaw Med. Univ. 22, 759–766 (2013).

Marteau, P., Guyonnet, D., Lafaye de Micheaux, P. & Gelu, S. A randomized, double-blind, controlled study and pooled analysis of two identical trials of fermented milk containing probiotic Bifi dobacterium lactis CNCM I-2494 in healthy women reporting minor digestive symptoms.

Neurogastroenterol. Motil. Off. J. Eur. Gastrointest. Motil. Soc. 25, 331–e252 (2013).

Gawro ska, A., Dziechciarz, P., Horvath, A. & Szajewska, H. A randomized double-blind placebo-controlled trial of Lactobacillus GG for abdominal pain disorders in children.

Aliment. Pharmacol. Ther. 25, 177–184 (2007).

Del Piano, M. et al. The use of probiotics in healthy volunteers with evacuation disorders and hard stools: a double-blind, randomized, placebo-controlled study.

J. Clin. Gastroenterol. 44 Suppl 1, S30–34 (2010).

Zhang, L., Su, P., Henriksson, A., O’Rourke, J. & Mitchell, H. Investigation of the immunomodulatory effects of Lactobacillus casei and Bifi dobacterium lactis on Helicobacter pylori infection.

Helicobacter 13 :183–190 (2008).

Dylag, K., Hubalewska-Mazgaj, M., Surmiak, M., Szmyd, J. & Brzozowski, T. Probiotics in the mechanism of protection against gut inflammation and therapy of gastrointestinal disorders.

Curr. Pharm. Des. 20, 1149–1155 (2014).